Intervention not reported
Haematological Thrombocytopenia · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Intervention not reported
All adverse events · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · adults with renal vasculitis for maintenance therapy
Azathioprine may leads to lower death compared with methotrexate (low certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in relapse compared with methotrexate (low certainty).
1 finding from 1 review
Adverse event causing death or study drug discontinuation · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in adverse events causing death or study drug discontinuation compared with methotrexate (low certainty).
1 finding from 1 review
Severe adverse events · adults with renal vasculitis for maintenance therapy
Azathioprine may leads to lower severe adverse events compared with methotrexate (low certainty).
1 finding from 1 review
Death · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Kidney function · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · adults with renal vasculitis for maintenance therapy
Leflunomide showed no clear difference in relapse compared with methotrexate (low certainty).
1 finding from 1 review
Serious adverse events* · adults with renal vasculitis for maintenance therapy
Leflunomide showed no clear difference in serious adverse events* compared with methotrexate (low certainty).
1 finding from 1 review
Infection · adults with renal vasculitis for maintenance therapy
Leflunomide showed no clear difference in infection compared with methotrexate (low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
1 finding from 1 review
Clinical remission1 · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission1 compared with methotrexate (low certainty).
1 finding from 1 review